Literature DB >> 22260968

Screening active compounds acting on the epidermal growth factor receptor from Radix scutellariae via cell membrane chromatography online coupled with HPLC/MS.

Huaizhen He1, Shengli Han, Tao Zhang, Jie Zhang, Sicen Wang, Jingjing Hou.   

Abstract

Radix scutellariae is a traditional Chinese medicine (TCM) and has many pharmacological effects, including antiviral, antibacterial, antifungal, antipyretic, hypotensive, anti-inflammatory and anti-anaphylaxis effects. However, few studies have screened the active compounds in this complex product for tumor therapy. In this study, a two-dimensional online method was developed to screen the active compounds from Radix scutellariae acting on the epidermal growth factor receptor. The screening results showed that wogonin from Radix scutellariae was the targeted component which acted on epidermal growth factor receptor specificity. The in vitro inhibitory activity of wogonin on the viability of cells with high epidermal growth factor receptor expression was tested using the MTT assay. In the dosage range of 0.40-50.0 μM, inhibition of HEK293/EGFR by wogonin was 8.94 ± 0.2, 20.64 ± 5.10, 34.16 ± 5.90 and 69.03 ± 7.80 at the concentrations of 0.4 × 10(-6), 2 × 10(-6), 10 × 10(-6) and 50 × 10(-6) molL(-1), respectively. These results showed that wogonin inhibited the growth of cells with high epidermal growth factor receptor expression in a dose-dependent manner.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22260968     DOI: 10.1016/j.jpba.2011.12.025

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  7 in total

1.  Characterization of anti-leukemia components from Indigo naturalis using comprehensive two-dimensional K562/cell membrane chromatography and in silico target identification.

Authors:  Xunxun Wu; Xiaofei Chen; Jia Dan; Yan Cao; Shouhong Gao; Zhiying Guo; Philipp Zerbe; Yifeng Chai; Yong Diao; Lei Zhang
Journal:  Sci Rep       Date:  2016-05-06       Impact factor: 4.379

Review 2.  Advances of wogonin, an extract from Scutellaria baicalensis, for the treatment of multiple tumors.

Authors:  Xue Wu; Haijun Zhang; Jumah Masoud Mohammad Salmani; Rong Fu; Baoan Chen
Journal:  Onco Targets Ther       Date:  2016-05-17       Impact factor: 4.147

3.  An activity-integrated strategy of the identification, screening and determination of potential neuraminidase inhibitors from Radix Scutellariae.

Authors:  Wei Liu; Huilin Wang; Bo Zhu; Chengqian Yin; Shuyang Chen; Jin Li; Xie-An Yu; John Teye Azietaku; Mingrui An; Xiu-Mei Gao; Yan-Xu Chang
Journal:  PLoS One       Date:  2017-05-09       Impact factor: 3.240

4.  Wogonin as a targeted therapeutic agent for EBV (+) lymphoma cells involved in LMP1/NF-κB/miR-155/PU.1 pathway.

Authors:  Xue Wu; Ping Liu; Haijun Zhang; Yuan Li; Jumah Masoud Mohammad Salmani; Fei Wang; Ke Yang; Rong Fu; Zhewei Chen; Baoan Chen
Journal:  BMC Cancer       Date:  2017-02-21       Impact factor: 4.430

5.  Network Pharmacology-Based Strategy for Predicting Therapy Targets of Traditional Chinese Medicine Xihuang Pill on Liver Cancer.

Authors:  Xu Zhao; Jian Hao; Sinuan Chen
Journal:  Evid Based Complement Alternat Med       Date:  2020-03-14       Impact factor: 2.629

Review 6.  The Therapeutic Potential of Wogonin Observed in Preclinical Studies.

Authors:  Javad Sharifi-Rad; Jesús Herrera-Bravo; Luis A Salazar; Shabnum Shaheen; Seyed Abdulmajid Ayatollahi; Farzad Kobarfard; Muhammad Imran; Ali Imran; Luísa Custódio; María Dolores López; Mauricio Schoebitz; Miquel Martorell; Manoj Kumar; Hafiz Ansar Rasul Suleria; William C Cho
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-15       Impact factor: 2.629

7.  Number 2 Feibi Recipe Reduces PM2.5-Induced Lung Injury in Rats.

Authors:  Zhaoheng Liu; Wei Wang; Fang Cao; Shuo Liu; Xinxin Zou; Guodong Li; Haojie Yang; Yang Jiao
Journal:  Evid Based Complement Alternat Med       Date:  2018-01-09       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.